Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 12/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153477 | 0.73 | CA2 (0.45) | PTPN1PTGS2PTGS1CA2PTPN11 | |
| SCHEMBL7527132 | 0.71 | PTPN1 (0.66) | PTPN1PTGS2PTGS1CA2PTPN11 | |
| SCHEMBL6658979 | 0.67 | CA2 (0.67) | PTGS2PTGS1CA2CA1SMN1; SMN2 | |
| SCHEMBL10625554 | 0.66 | CA2 (0.66) | PTGS2PTGS1CA2CA1 | |
| SCHEMBL8318603 | 0.66 | PTPN1 (0.41) | PTPN1PTGS2PTGS1CA2PTPN11 | |
| SCHEMBL17917630 | 0.63 | CA2 (0.50) | PTGS2PTGS1CA2CA1 | |
| SCHEMBL9202460 | 0.63 | CA2 (0.44) | PTPN1PTGS2PTGS1CA2PTPN11 | |
| SCHEMBL5645014 | 0.63 | MEN1 (0.44) | CA2CA1SMN1; SMN2 | |
| SCHEMBL688320 | 0.62 | PTPN11 (0.61) | PTPN1CA2PTPN11CA1MAPK1 | |
| SCHEMBL1419244 | 0.61 | CA2 (0.53) | PTPN1PTGS2PTGS1CA2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0963755-A2 | Use of benzopyranes for preventing allograft rejection | Pfizer Products Inc. (US) | 1999-12-15 | — | — | EP | claimed |
| EP-0943339-A2 | Method of preventing allograft rejection | Pfizer Products Inc. (US) | 1999-09-22 | — | — | EP | claimed |
| EP-0836850-A2 | Method of preventing allograft rejection | PFIZER INC. (US) | 1998-04-22 | — | — | EP | claimed |
| EP-0963755-A2 | Use of benzopyranes for preventing allograft rejection | Pfizer Products Inc. (US) | 1999-12-15 | — | — | EP | disclosed |
| EP-0943339-A2 | Method of preventing allograft rejection | Pfizer Products Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5948813-A | Method of preventing allograft rejection | PFIZER INC. (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0836850-A2 | Method of preventing allograft rejection | PFIZER INC. (US) | 1998-04-22 | — | — | EP | disclosed |